Home Culture CloseTo Nutrition Experts Research Reports Books Products iHealth Special topic
iHealth
iHealth
Position:Maitake > iHealth > 浏览文章

New interventional therapy for liver malignant tumors

Source:Guangming Daily Date:2021/10/13 14:32:16

Abstract:This new technology will become a new heavy weapon for China to conquer liver cancer. a few days ago, the main knife team led by Dong Jiahong, academician of the Chinese Academy of engineering and President of Beijing Tsinghua Changgeng hospital, successfully implemented Chinas first licensed yttrium resin microspheres for the clinical treatment of liver cancer in Boao, Hainan, This marks a new international precision interventional therapy scheme in the field of liver malignant tumor treatment in China. Dong Jiahong said that the accurate operation of yttrium resin microspheres by doctors to achieve down-stage treatment or potential radical cure for patients with advanced liver cancer is a landmark advanced achievement in the history of liver cancer treatment in China.

"This new technology will become a new heavy weapon for China to conquer liver cancer." a few days ago, the main knife team led by Dong Jiahong, academician of the Chinese Academy of engineering and President of Beijing Tsinghua Changgeng hospital, successfully implemented China's first licensed yttrium [90Y] resin microspheres for the clinical treatment of liver cancer in Boao, Hainan, This marks a new international precision interventional therapy scheme in the field of liver malignant tumor treatment in China. Dong Jiahong said that the accurate operation of yttrium [90Y] resin microspheres by doctors to achieve down-stage treatment or potential radical cure for patients with advanced liver cancer is a landmark advanced achievement in the history of liver cancer treatment in China.

"Yttrium [90Y] resin microspheres are like a 'super nuclear bomb' that can be accurately delivered to conquer tumors." Dong Jiahong introduced that the treatment scheme uses the world's leading interventional technology to inject yttrium [90Y] resin microspheres into liver blood vessels to release high energy β Radiation can instantly kill tumor cells in a short distance and has little effect on normal liver tissue and surrounding environment. At the same time, yttrium [90Y] resin microspheres alone or in combination with other comprehensive treatment methods such as biology, immunity and targeting will benefit the majority of patients with liver cancer.

It is understood that liver cancer is known as the "king of cancer". There are 400000 new cases of liver cancer in China every year, accounting for about 47.6% of the new cases of liver cancer in the world. Most patients were found to be in the middle and advanced stage. Only 20% ~ 30% of patients with liver cancer can be removed by surgery, and the recurrence rate within 5 years is still as high as 60% ~ 70%. The operation was a 34 year old male patient with a history of hepatitis B, who was diagnosed as primary liver cancer by various examinations. He had exceeded the standard of liver transplantation for all kinds of liver cancer. At the same time, the volume of reserved liver was less than 40%, which could not be resected routinely. After many discussions by experts, it is determined that yttrium [90Y] resin microspheres are the best choice for patients.

"The operation successfully injected yttrium [90Y] resin microspheres into the tumor. During the operation, the patient's vital signs were stable and there were no adverse reactions. The whole operation was completed in less than an hour. In the future, the speed and efficiency of treatment will continue to improve, and the patient's treatment experience will be better optimized." Zhang Lin, deputy chief physician of hepatobiliary interventional Department of Beijing Tsinghua Changgeng hospital, and Niu Huimin, director of interventional Department of Hainan Cancer Hospital, introduced the operation.

Li Sijin, chairman of the nuclear medicine branch of the Chinese Medical Association and President of Shanxi Medical University, told reporters that in June this year, eight ministries and commissions jointly issued the medium and long term development plan for medical isotopes (2021-2035), which is the first programmatic document issued in China for the application of nuclear technology in the field of medical and health care, fully affirming the role of nuclear medicine in the early diagnosis of major diseases It plays a unique role in accurate clearance and reasonable diagnosis and treatment of small lesions. As a global innovative radioisotope drug, the landing of yttrium [90Y] resin microspheres in Boao, Hainan is like an engine, which will start and accelerate the long-term development and profound change of nuclear medicine in China.

Source: Guangming Daily

https://finance.sina.com.cn/tech/2021-10-13/doc-iktzscyx9371067.shtml


Special statement:
1、All the information in this website is available on the Internet, and all of them contain the original text or the source of quotation. You can check the original text;
2、The information on this website is only for learning and popular science, not for any other purpose. Please read it rationally;
3、If the information contained in this website violates your rights, please contact us, we will delete it at the first time, and thank you for your prompt;;
Course of literature review methods:
1、Open the information of the website, where there is the reference source of the information, and click open;
2、Read or download the literature online, most of which are charged. Please download according to your needs and abilities;
3、Baidu search sci-hub, then you can get unexpected download method;
4、Literature Translation: you can easily read the literature by using the "Zhiyun" literature tool;
5、Online English Literature: you can use Baidu translation and other translation tools, or use "copytranslator" to read online more conveniently;
Famous medical literature databases at home and abroad:
Open The Tool
Special statement: the information of this website is for learning reference only. It does not mean that you agree with its point of view or confirm its description. It is not used as any other guidance basis. Please read it rationally。
Copyright R 2012 ChinaMaitake.com All Rights Reserved.

ICP record No.:沪ICP备2020037409号-5
Declare:The information of this website is for reference only, not for any consumption guidance.
ICP record No.:沪ICP备2020037409号-5

Follow Maitake
Back To Home